Sanofi has formally requested that the FDA remove its type 1 diabetes drug, teplizumab, from Commissioner Marty Makary's expedited review program. This request follows an unusual intervention by acting CDER director Tracy Beth Høeg, who reportedly overruled career staff scientists regarding the drug's approval. The agency subsequently missed its decision deadline, raising concerns about political interference in the scientific review process.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.